Information for continuing education (CE) credit

# Who said you can’t teach an old drug new tricks? The use of post-transplant cyclophosphamide for acute graft-versus-host disease prevention

Activity date: January 26, 2021

Course director: Bailey Wise, PharmD

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety
2. After the course, you will receive an email with instructions and an access code that you will need to obtain your CE credit
3. **Complete the process no later than March 11, 2021**

Upon successful completion of the course requirements, you will be able to print your CE certificate and/or statement of credit for pharmacy education.

**Important note for pharmacists and pharmacy technicians**

All credit awarded to pharmacists and pharmacy technicians must be via CPE Monitor; paper certificates and e-certificates are not valid for licensure/certification submission.  Pharmacists and pharmacy technicians will be able to print individual statements of credit and their transcripts from their NABP e-profile created at [www.mycpemonitor.net](http://www.mycpemonitor.net) or [www.nabp.net](http://www.nabp.net).

1. Please provide an accurate **NABP ID number** and **date of birth** (**mm/dd** – do not include birth year)
2. Vizient will upload your **NABP ID number** and **date of birth** into CPE Monitor within 24 hours after the completion of all steps required to receive credit.

If your **NABP ID number** and/or **date of birth** are returned as invalid after the upload, Vizient will make one attempt to contact you for corrections within a 45-day window. After the 45-day window expires, Vizient will not accept the information, and Vizient will not be able to process your CE credit.

**Pharmacist learning objectives**

1. Explain the pathophysiology of acute graft versus host disease (aGVHD)
2. Review the clinical signs and symptoms of aGVHD
3. Determine the adverse effects caused by the therapeutic agents used for the prevention of aGVHD
4. Evaluate the literature on the recent advancements in therapies used for prevention of aGVHD

**Pharmacy technician learning objectives**

1. Recognize brand and generic names of pharmacological options used for the prevention of acute graft versus host disease
2. Identify the different dosage forms of the pharmacological options used for the prevention of aGVHD



**Joint Accreditation Statement:**

In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Designation Statements:**

#### PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

Universal Activity Number: JA0006103-9999-21-077-L01-P

Universal Activity Number: JA0006103-9999-21-077-L01-T

### CEU

Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

**CONFLICT OF INTEREST/CONTENT VALIDATION POLICY:**

As an accredited provider of continuing medical education/continuing education Vizient is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. Vizient requires all potential faculty and program planners, in advance, to disclose financial relationships with relevant commercial interests. Vizient uses that information to determine whether prospective contributors have potential conflicts of interest. If significant relationships are disclosed, Vizient assesses how those potential conflicts of interest may affect CME/CE content. Vizient requires that all conflicts of interest be resolved prior to participation in the activity. Vizient is committed to resolving potential conflicts of interest, although if contributors have significant relationships that cannot be reconciled, Vizient reserves the right to prohibit participation. Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

### DISCLOSURE STATEMENTS:

### Current accrediting agency guidelines and Vizient policy state that participants in educational activities should be made aware of any affiliation or financial interest that may affect the presentation and if there will be any discussion of unapproved or investigative use of commercial products/devices. Each planning committee member, reviewer and presenter has completed a Disclosure of Relevant Financial Relationships form.

Relevant financial relationships: Planning committee members and presenters have nothing to disclose

The presenter will discuss off-label use of drugs

### Planning committee members

**Jessica Foy, PharmD, BCPS, BCOP**

Clinical Pharmacy Specialty, Bone Marrow Transplant

Ochsner Medical Center

**Breanne Peyton-Thomas, PharmD, BCOP**

Clinical Pharmacy Speciality, Bone Marrow Transplant

Ochsner Medical Center

**Bailey Wise, PharmD, BCPS**

Clinical Pharmacist

Ochsner Medical Center

### Presenter

**Shima Shafiyan, PharmD**

PGY-2 Oncology Pharmacy Resident

Ochsner Medical Center